Thiamine Intervention and Coronary Artery Bypass Grafting
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age60-80
SponsorUniversity of California, Los Angeles
About this trial
The purpose of this study is to gain a better understanding of the association between brain changes and cognitive deficits in coronary heart disease (CHD) patients undergoing coronary artery bypass grafting (CABG) and whether a low-cost thiamine intervention can be used to reduce post-CABG cognitive issues in CHD subjects.
Eligibility criteria
Qualifiers
Patients with Coronary Heart Disease (CHD) scheduled for Bypass Grafting (CABG)
Thiamine deficiency before CABG
European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) >1.5%
Off-pump surgery
Disqualifiers
Dementia at baseline [Montreal Cognitive Assessment (MoCA) <21 within 5 days before CABG]
Current in-take of thiamine
Known thiamine allergy
Uncontrolled blood glucose levels
Trial design
Treatments tested in this trial
- Thiamine
- Placebo
Treatment groups
52 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of California, Los Angeles
Lead sponsor
National Institute on Aging (NIA)
Collaborator
Source ClinicalTrials.gov